-
Je něco špatně v tomto záznamu ?
MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes
M. Mráz, Š. Pospíšilová, K. Malinová, I. Šlapák, J. Mayer
Jazyk angličtina Země Velká Británie
Typ dokumentu práce podpořená grantem
Grantová podpora
NR9293
MZ0
CEP - Centrální evidence projektů
NLK
Medline Complete (EBSCOhost)
od 1998-01-01
- MeSH
- chronická lymfatická leukemie etiologie genetika MeSH
- down regulace MeSH
- lidé MeSH
- mikro RNA genetika MeSH
- mutace MeSH
- nádorový supresorový protein p53 genetika MeSH
- regulace genové exprese u nádorů MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- práce podpořená grantem MeSH
MicroRNAs (miRNAs) are short, non-coding RNAs, which function as evolutionary conserved regulators of a gene expression. They have essential roles in development, cell differentiation, proliferation, apoptosis and chromosome structure. MiRNAs constitute about 3-5% of predicted genes in the human genome (i.e. about 1000); and 20-30% of the protein-coding genes are estimated to be regulated by the miRNAs. The primary evidence that miRNAs possibly act as a novel class of oncogenes/tumor-suppressors comes from the discovery of the miR-15a and miR-16-1 in 13q14 region deleted in chronic lymphocytic leukemia (CLL). Moreover, miRNA signatures have been used to classify tumor types. There have recently been several reports on the miRNAs role in CLL pathogenesis and disease subtypes (according to IgV(H) mutation status). In this report, we will review the published observations and present our miRNA profiling data in aggressive CLL with TP53 abnormalities (deletion and/or mutation of p53 gene). We have identified a deregulated miRNA expression pattern (down regulation of miR-34a, miR-29 and miR-17-5p) in these samples, compared to cells with wild-type TP53. It has previously been shown that miR-34a is directly regulated by p53 and targets BCL-2, miR-29c regulates the MCL-1 and TCL-1 proto-oncogenes and the miR-17-5p targets important cell cycle regulatory molecules. Consequently, these three miRNAs could potentially play important roles in the pathogenesis of aggressive CLL.
- 000
- 02900naa 2200349 a 4500
- 001
- bmc11020696
- 003
- CZ-PrNML
- 005
- 20140718134736.0
- 008
- 110629s2009 xxk e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Mráz, Marek $7 xx0122131 $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematooncology, University Hospital Brno and Medical Faculty MU, Brno, Czech Republic
- 245 10
- $a MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes / $c M. Mráz, Š. Pospíšilová, K. Malinová, I. Šlapák, J. Mayer
- 314 __
- $a Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematooncology, University Hospital Brno and Medical Faculty MU, Brno, Czech Republic. marek.mraz@email.cz
- 520 9_
- $a MicroRNAs (miRNAs) are short, non-coding RNAs, which function as evolutionary conserved regulators of a gene expression. They have essential roles in development, cell differentiation, proliferation, apoptosis and chromosome structure. MiRNAs constitute about 3-5% of predicted genes in the human genome (i.e. about 1000); and 20-30% of the protein-coding genes are estimated to be regulated by the miRNAs. The primary evidence that miRNAs possibly act as a novel class of oncogenes/tumor-suppressors comes from the discovery of the miR-15a and miR-16-1 in 13q14 region deleted in chronic lymphocytic leukemia (CLL). Moreover, miRNA signatures have been used to classify tumor types. There have recently been several reports on the miRNAs role in CLL pathogenesis and disease subtypes (according to IgV(H) mutation status). In this report, we will review the published observations and present our miRNA profiling data in aggressive CLL with TP53 abnormalities (deletion and/or mutation of p53 gene). We have identified a deregulated miRNA expression pattern (down regulation of miR-34a, miR-29 and miR-17-5p) in these samples, compared to cells with wild-type TP53. It has previously been shown that miR-34a is directly regulated by p53 and targets BCL-2, miR-29c regulates the MCL-1 and TCL-1 proto-oncogenes and the miR-17-5p targets important cell cycle regulatory molecules. Consequently, these three miRNAs could potentially play important roles in the pathogenesis of aggressive CLL.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a down regulace $7 D015536
- 650 _2
- $a regulace genové exprese u nádorů $7 D015972
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a chronická lymfatická leukemie $x etiologie $x genetika $7 D015451
- 650 _2
- $a mikro RNA $x genetika $7 D035683
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a nádorový supresorový protein p53 $x genetika $7 D016159
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pospíšilová, Šárka, $d 1969- $7 xx0101843 $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematooncology, University Hospital Brno and Medical Faculty MU, Brno, Czech Republic
- 700 1_
- $a Plevová, Karla $7 xx0158852 $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematooncology, University Hospital Brno and Medical Faculty MU, Brno, Czech Republic
- 700 1_
- $a Šlapák, Ivo, $d 1952- $7 jn20000402849 $u Department of Paediatric Otorhinolaryngology, University Hospital Brno and Medical Faculty MU, Brno, Czech Republic
- 700 1_
- $a Mayer, Jiří, $d 1960- $7 nlk20000083651 $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematooncology, University Hospital Brno and Medical Faculty MU, Brno, Czech Republic
- 773 0_
- $t Leukemia & Lymphoma $g Roč. 50, č. 3 (2009), s. 506-509 $w MED00003140
- 910 __
- $a ABA008 $b x $y 2 $z 0
- 990 __
- $a 20110721122628 $b ABA008
- 991 __
- $a 20140718135039 $b ABA008
- 999 __
- $a ok $b bmc $g 864223 $s 727087
- BAS __
- $a 3
- BMC __
- $a 2009 $b 50 $c 3 $d 506-509 $m Leukemia & lymphoma $n Leuk Lymphoma $x MED00003140
- GRA __
- $a NR9293 $p MZ0
- LZP __
- $a 2011-3B09/BBjvme